{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-024136","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.500980+00:00","generated_at":"2026-06-15T03:46:21.549103+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Femasys Q1 2023 net loss $2.95M; Health Canada approves FemaSeed & FemCerv","bullets":["Net loss of $2,946,257 ($0.25 basic & diluted EPS) vs $2,883,030 ($0.24) YoY.","Revenue $293,984, down 8.5% YoY; U.S. sales up 11.6%, international sales nil.","Raised $3.9M in registered direct offering closed April 20, 2023; cash runway into Q2 2024.","Health Canada approved FemaSeed (infertility) and FemCerv (cervical sampler) in April/May 2023.","Cash and equivalents $10.2M as of March 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-024136","json":"https://secwatch.observer/filing/0001140361-23-024136.json","markdown":"https://secwatch.observer/filing/0001140361-23-024136.md","text":"https://secwatch.observer/filing/0001140361-23-024136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/0001140361-23-024136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/brhc20052828_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:46:21.549103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a91d760fa3916e9d2c85d8b4ac9ebacdf47036e1","claim":"FEMASYS INC reported the first quarter ended March 31, 2023 results: revenue $293,984, net income $2,946,257, EPS $0.25 per basic and diluted share.","evidence_excerpt":"in facility and other overhead costs mainly for directors & officers (D&O) insurance, and a decrease in legal and certain professional costs. • Sales decreased by $27,421 to $293,984 for the three months ended March 31, 2023, from $321,405 for the same period last year. U.S. sales, however, increased by $30,624, or 11.6%, for the three months ended March 31,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/0001140361-23-024136-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$293,984"},{"label":"Net income","value":"$2,946,257"},{"label":"EPS","value":"$0.25 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}